| Abstract P156 – Table 1. Baseline demographics/clinical characteristics of TN and TE participants by weight change. | ||||||
|---|---|---|---|---|---|---|
| TN (n = 727) | TE (n = 1939) | |||||
| Characteristic | Absolute weight lossa (n = 153 [21%]) | No weight change (n = 88 [12%]) | Absolute weight gaina (n = 486 [67%]) | Absolute weight lossa (n = 430 [22%]) | No weight change (n = 225 [12%]) | Absolute weight gaina (n = 1284 [66%]) |
| Male, n (%) | 142 (93) | 79 (90) | 436 (90) | 381 (89) | 198 (88) | 1072 (84) |
| Median (Q1, Q3) age, years | 36.0 (29 to 45) | 34.5 (29 to 46) | 39.0 (31 to 46) | 48.0 (38 to 55) | 43.0 (36 to 51) | 47.0 (38 to 54) |
| ART third agent: NNRTI, n (%) | 60 (39) | 38 (43) | 120 (25) | 144 (34) | 125 (56) | 440 (34) |
| ART third agent: INSTI, n (%) | 93 (61) | 50 (57) | 366 (75) | 286 (67) | 100 (44) | 844 (66) |
| ART backbone: F/TDF, n (%) | 70 (46) | 59 (67) | 142 (29) | 96 (22) | 129 (57) | 228 (18) |
| ART backbone: F/TAF, n (%) | 83 (54) | 29 (33) | 344 (71) | 334 (78) | 96 (43) | 1056 (82) |
| Pre‐switch efavirenz, n (%) | N/A | N/A | N/A | 31 (5) | 16 (5) | 113 (6) |
| Switch: F/TDF to F/TAF ‐ no, n (%) | N/A | N/A | N/A | 205 (48) | 153 (68) | 505 (39) |
| Switch: F/TDF to F/TAF ‐ yes, n (%) | N/A | N/A | N/A | 185 (43) | 69 (31) | 660 (51) |
| Switch: ABC/3TC to F/TAF ‐ yes, n (%) | N/A | N/A | N/A | 40 (9) | 3 (1) | 119 (9) |
| Median (Q1, Q3) baseline weight, kg | 75.8 (69 to 85) | 73.5 (64 to 84) | 72.0 (65 to 82) | 77.0 (70 to 88) | 74.0 (66 to 84) | 74.9 (66 to 84) |
| Median (Q1, Q3) baseline BMI, kg/m2 | 23.7 (21.8 to 25.6) | 23.3 (20.9 to 25.2) | 23.1 (21.4 to 25.5) | 24.9 (22.7 to 27.8) | 23.7 (21.6 to 25.6) | 24.2 (21.8 to 26.9) |
| Median (Q1, Q3) weight change at 12 months, % | ‐2.7 (‐5 to ‐1.4) | 0 (0 to 0) | 5.4 (2.8 to 9.5) | ‐2.8 (‐5.2 to ‐1.4) | 0 (0 to 0) | 3.8 (1.8 to 6.8) |
| ≥10% weight gainb at 12 months, n (%) | N/A | N/A | 229 (47) | N/A | N/A | 451 (35) |
| ≥10% weight lossb at 12 months, n (%) | 8 (5) | N/A | N/A | 40 (9) | N/A | N/A |
| Any comorbidity, n (%) | 13 (9) | 9 (10) | 63 (13) | 144 (34) | 44 (20) | 377 (29) |
| Comedications associated with WG,c n (%) | 13 (9) | 5 (6) | 65 (13) | 68 (16) | 29 (13) | 217 (17) |
| Comedications associated with WL,d n (%) | 2 (1) | 1 (1) | 26 (5) | 24 (6) | 8 (4) | 59 (5) |
| Median (Q1, Q3) CD4 count, cells/μL | 429 (309 to 582) | 391 (302 to 511) | 368 (221 to 534) | 640 (458 to 840) | 558 (383 to 754) | 609 (406 to 823) |
| Median (Q1, Q3) HIV‐1 RNA, log10 copies/mL | 4.35 (3.72 to 4.81) | 4.48 (4.12 to 4.82) | 4.64 (4.08 to 5.12) | 1.59 (1.28 to 1.69) | 1.69 (1.46 to 1.69) | 1.57 (1.28 to 1.69) |
| Late presenters,e n (%) | 55 (36) | 37 (42) | 229 (47) | N/A | N/A | N/A |
aWeight loss/gain includes any weight change;
b≥10% WG: yes = ≥10% WG, no = ≥–5% to <10% weight change; ≥10% WL: yes = ≥–10%, no = <–10% to <5% weight change;
call individual comedications were classified as to whether they had an effect on WG, WL or none; drug classes of comedications with a known WG effect included: insulin, antidepressants, psychotropic agents, antiepileptics, antipsychotics, contraceptives, corticosteroids, antihistamines, beta‐androgenic blockers, anti‐gout preparation;
dall comedications were classified as to whether they had an effect on WG, WL or none; drug classes of comedications with a known WL effect included: antidepressants, antiepileptics, corticosteroids, beta‐androgenic blockers;
eCD4 <350 μL and/or CDC stage A3, B3 or any C stage (EU definition).